9.46
前日終値:
$8.86
開ける:
$8.84
24時間の取引高:
154.02K
Relative Volume:
0.45
時価総額:
$248.91M
収益:
$56.65M
当期純損益:
$-53.31M
株価収益率:
-4.6277
EPS:
-2.0442
ネットキャッシュフロー:
$-40.75M
1週間 パフォーマンス:
+11.16%
1か月 パフォーマンス:
+15.93%
6か月 パフォーマンス:
+17.22%
1年 パフォーマンス:
-22.65%
Cvrx Inc Stock (CVRX) Company Profile
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CVRX
Cvrx Inc
|
9.46 | 233.12M | 56.65M | -53.31M | -40.75M | -2.0442 |
|
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-09 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-01-14 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-07-11 | 繰り返されました | Lake Street | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2024-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 開始されました | Lake Street | Buy |
| 2022-07-18 | 開始されました | Craig Hallum | Buy |
| 2021-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-26 | 開始されました | Piper Sandler | Overweight |
| 2021-07-26 | 開始されました | William Blair | Outperform |
すべてを表示
Cvrx Inc (CVRX) 最新ニュース
Patterns Watch: Is CVRX a speculative investmentPortfolio Profit Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sectors Review: Is CVRX a strong candidate for buy and holdInsider Buying & Technical Analysis for Trade Confirmation - baoquankhu1.vn
IMA,CVRX Volatility & Greeks - Finviz
How (CVRX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone - Traders Union
SGP,CVRX Volatility & Greeks - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out | NDAQ:CVRX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (NASDAQ:CVRX) Q4 2025 earnings call transcript - MSN
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IMA,CVRX Dividends - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - ACCESS Newswire
CVRx’s BENEFIT-HF Trial: New Heart Failure Study Sets Up a Key Catalyst for Investors - tipranks.com
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
CVRx Inc Stock (ISIN: US12674F1003) Gains Momentum on Heart Failure Device Adoption Amid Medtech Sec - AD HOC NEWS
Sentiment Review: Will CVRX benefit from government policy2026 Price Swings & Precise Buy Zone Identification - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
EPS Watch: How is CVRx Inc managing supply chain issuesOptions Play & Daily Stock Momentum Reports - baoquankhu1.vn
Trading Systems Reacting to (CVRX) Volatility - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Stockholders to Connect - ACCESS Newswire
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Continues – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - The AI Journal
FinancialContentCVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Levels Update: Whats the beta of CVRx Inc stock2026 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
First Barostim procedure at Ascension Alexian Brothers backed by CVRx - Traders Union
CVRx (CVRX) CMO granted 62K options, 41K RSUs and sells 1.3K shares - Stock Titan
Exit Recap: Will CVRx Inc announce a stock splitMarket Rally & Long-Term Growth Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (NASDAQ:CVRX) Sees Significant Increase in Short Interest - MarketBeat
IMA,CVRX Options - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Investors to Reach Out - ACCESS Newswire
CVRx enables first Barostim implant at Baptist Medical Center expanding heart failure treatment options - Traders Union
Buybacks Report: Does CVRx Inc meet Warren Buffetts criteria2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
CVRx outlines $55M-$57M revenue target for 2025 as sales force transition nears completion - MSN
CVRX SEC FilingsCvrx, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Energy Moves: Why is CVRx Inc stock going downMarket Sentiment Review & Smart Allocation Stock Reports - baoquankhu1.vn
CVRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
CVRx shares rise on CMS inclusion for Barostim implant procedure - MSN
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Quarterly Earnings: Is CVRx Inc. stock affected by interest rate hikesTrade Risk Summary & High Return Stock Watch Alerts - Naître et grandir
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Cvrx Inc. (CVRX) Affects Rotational Strategy Timing - Stock Traders Daily
Risk Check: Whats the beta of CVRx Inc stock2025 Macro Impact & Weekly High Return Stock Forecasts - baoquankhu1.vn
Barostim device transforms life after severe heart failure, CVRx asserts - Traders Union
Trend Recap: Why is CVRx Inc stock going downPortfolio Return Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
CVRX Earnings History & Surprises | EPS & Revenue Results | CVRX INC (NASDAQ:CVRX) - ChartMill
CVRx to present late-breaking THT2026 data in clinical webinar - Traders Union
CVRx Introduces New Performance-Based Executive Stock Unit Plan - The Globe and Mail
CVRx (CVRX) lists Chief HR Officer Gregory Morrison as insider on Form 3 - Stock Titan
CVRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cvrx Inc (CVRX) 財務データ
収益
当期純利益
現金流量
EPS
Cvrx Inc (CVRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
大文字化:
|
ボリューム (24 時間):